TNF blockers and hepatosplenic T-cell lymphoma linked
FDA has received reports of hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease and ulcerative colitis being treated with tumor necrosis factor blockers, azathioprine, and mercaptopurine.
FDA has received reports of hepatosplenic T-cell lymphoma (HSTCL), a rare, aggressive cancer of white blood cells that usually is fatal, in adolescents and young adults with Crohn's disease and ulcerative colitis being treated with tumor necrosis factor (TNF) blockers (ie, infliximab, etanercept, adalimumab, certolizumab pegol, and golimumab), azathioprine, and mercaptopurine.
Several cases have occurred in patients being treated for rheumatoid arthritis and in 1 patient with psoriasis.
Although HSTCL was reported most often in those patients receiving a combination of medicines that suppress the immune system, including the TNF blockers, azathioprine, and/or mercaptopurine, there were some reports of HSTCL in patients who received azathioprine or mercaptopurine as monotherapies.
Pediatric cancer survivors and cardiovascular toxicity, disease risk
March 21st 2025Pediatric cancer survivors can be vulnerable to cardiovascular disease in the short- or long-term with increased recognition of cardiotoxic cancer treatments, as 5-year survival rates for children are greater than 85%.
